OmniAb (OABI) Registration Filing summary

Company overview and business model

• Licenses advanced antibody discovery technology to pharmaceutical, biotech, and academic partners for next-generation therapeutic development.

• Platform leverages proprietary transgenic animals and computational methods to generate optimized antibody candidates.

• Offers both integrated end-to-end and customizable solutions to address industry challenges in drug discovery.

• Corporate history includes re-domestication to Delaware and a merger with OmniAb Operations, previously owned by Ligand Pharmaceuticals.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by selling stockholders; all net proceeds go to the selling stockholders.

• Company bears registration and related offering expenses, while selling stockholders cover their own selling costs.

Risk factors and disclosures

• Investment involves risks detailed in incorporated annual, quarterly, and current reports, with potential for total loss of investment.

• Forward-looking statements are subject to significant uncertainties and actual results may differ materially.